TY - JOUR T1 - Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients JF - The Journal of Rheumatology JO - J Rheumatol SP - 1993 LP - 1994 DO - 10.3899/jrheum.150230 VL - 42 IS - 10 AU - SARA MONTI AU - SILVIA BREDA AU - VITTORIO GROSSO AU - MONICA TODOERTI AU - CARLOMAURIZIO MONTECUCCO AU - ROBERTO CAPORALI Y1 - 2015/10/01 UR - http://www.jrheum.org/content/42/10/1993.abstract N2 - To the Editor:We read with interest the article by Reggia, et al1, a monocentric study analyzing the efficacy and safety of switching from intravenous (IV) to subcutaneous (SC) formulation of abatacept (ABA) in patients with rheumatoid arthritis. The authors report a relatively high risk of disease relapse (27%) occurring in a mean of 11 weeks after switching to SC administration. The study did not find any significant predictive factor for a switch failure. The concern that patients with a higher body mass index could receive lower cumulative doses compared to weight-tiered monthly infusions, leading to a significant influence on treatment efficacy, was not confirmed by this study, or by previous dose-finding trials and … Address correspondence to Dr. S. Monti; E-mail: sara.saramonti{at}gmail.com ER -